B. Riley analyst Mayank Mamtani lowered the firm’s price target on Novavax to $29 from $37 and keeps a Buy rating on the shares. The analyst cites uncertain COVID vaccine market dynamics and the company’s lack of leverage on balance sheet and pipeline diversification for the target drop. However, these are largely baked in with the stock’s continued underperformance, implying "room for meaningful impact from appropriate strategic choices," the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVAX:
- H.C. Wainwright reiterates Top Pick Buy on Novavax after partnership extension
- Novavax, U.S. government extend partnership
- Novavax call volume above normal and directionally bullish
- Novavax put volume heavy and directionally bearish
- Novavax Nuvaxovid COVID-19 vaccine approved in South Korea as adult booster